<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>A797</title>

<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Albertus Extra Bold";
	panose-1:2 14 8 2 4 3 4 2 2 4;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 6 4 5 2 3 4;}
@font-face
	{font-family:Albertus;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	background:navy;
	font-size:12.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:9.0pt;
	font-family:"Segoe UI",sans-serif;
	letter-spacing:.2pt;}
p.FronterPage, li.FronterPage, div.FronterPage
	{mso-style-name:FronterPage;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.Para10pt
	{mso-style-name:Para10pt;
	font-family:"Times New Roman",serif;}
p.PrefileFronterTitle, li.PrefileFronterTitle, div.PrefileFronterTitle
	{mso-style-name:PrefileFronterTitle;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:17.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.StylePrefileFronterTitleLeft, li.StylePrefileFronterTitleLeft, div.StylePrefileFronterTitleLeft
	{mso-style-name:"Style PrefileFronterTitle + Left";
	margin-top:0in;
	margin-right:-.2in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:17.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.BillHead
	{mso-style-name:BillHead;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BillHeading2
	{mso-style-name:BillHeading2;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BillLanguage
	{mso-style-name:BillLanguage;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.HangingAnAct, li.HangingAnAct, div.HangingAnAct
	{mso-style-name:HangingAnAct;
	mso-style-link:"HangingAnAct Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.HangingAnActChar
	{mso-style-name:"HangingAnAct Char";
	mso-style-link:HangingAnAct;
	letter-spacing:.2pt;}
span.11ptChar
	{mso-style-name:11ptChar;
	font-family:"Times New Roman",serif;}
span.BillHeadUnBold
	{mso-style-name:BillHeadUnBold;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
p.bpuBill, li.bpuBill, div.bpuBill
	{mso-style-name:bpuBill;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:26.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuHeadSpon, li.bpuHeadSpon, div.bpuHeadSpon
	{mso-style-name:bpuHeadSpon;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.bpuHeadSponChar
	{mso-style-name:bpuHeadSponChar;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuIntro, li.bpuIntro, div.bpuIntro
	{mso-style-name:bpuIntro;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.bpuLegislature, li.bpuLegislature, div.bpuLegislature
	{mso-style-name:bpuLegislature;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:24.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuNormText, li.bpuNormText, div.bpuNormText
	{mso-style-name:bpuNormText;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.bpuReprint, li.bpuReprint, div.bpuReprint
	{mso-style-name:bpuReprint;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:22.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.bpuSponsor, li.bpuSponsor, div.bpuSponsor
	{mso-style-name:bpuSponsor;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuState, li.bpuState, div.bpuState
	{mso-style-name:bpuState;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:32.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.charMarlett
	{mso-style-name:charMarlett;
	font-family:Marlett;}
p.ElevenPt, li.ElevenPt, div.ElevenPt
	{mso-style-name:ElevenPt;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPage12pt, li.FronterPage12pt, div.FronterPage12pt
	{mso-style-name:FronterPage12pt;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPageBillHeading, li.FronterPageBillHeading, div.FronterPageBillHeading
	{mso-style-name:FronterPageBillHeading;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
p.FronterPageNOCAPS, li.FronterPageNOCAPS, div.FronterPageNOCAPS
	{mso-style-name:FronterPageNOCAPS;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	font-size:12.0pt;
	font-family:"Times",serif;}
p.FronterPageTBox2, li.FronterPageTBox2, div.FronterPageTBox2
	{mso-style-name:FronterPageTBox2;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPageTextBox, li.FronterPageTextBox, div.FronterPageTextBox
	{mso-style-name:FronterPageTextBox;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.FronterSameAs, li.FronterSameAs, div.FronterSameAs
	{mso-style-name:FronterSameAs;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Pg2Footer, li.Pg2Footer, div.Pg2Footer
	{mso-style-name:Pg2Footer;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Style10pt
	{mso-style-name:"Style 10 pt";
	font-family:"Times New Roman",serif;}
p.StyleFronterPage11pt, li.StyleFronterPage11pt, div.StyleFronterPage11pt
	{mso-style-name:"Style FronterPage + 11 pt";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.StyleFronterPageLoweredby3pt, li.StyleFronterPageLoweredby3pt, div.StyleFronterPageLoweredby3pt
	{mso-style-name:"Style FronterPage + Lowered by  3 pt";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	position:relative;
	top:3.0pt;}
p.StyleFronterSameAsPatternSolid100White, li.StyleFronterSameAsPatternSolid100White, div.StyleFronterSameAsPatternSolid100White
	{mso-style-name:"Style FronterSameAs + Pattern\: Solid \(100%\) \(White\)";
	margin:0in;
	margin-bottom:.0001pt;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Style1, li.Style1, div.Style1
	{mso-style-name:Style1;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.Whereas
	{mso-style-name:Whereas;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
p.bpuWpGraphic, li.bpuWpGraphic, div.bpuWpGraphic
	{mso-style-name:bpuWpGraphic;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.LeftBrackt
	{mso-style-name:LeftBrackt;
	font-family:"Albertus Extra Bold",sans-serif;
	font-weight:bold;}
span.RightBrackt
	{mso-style-name:RightBrackt;
	font-family:"Albertus Extra Bold",sans-serif;
	font-weight:bold;}
span.Superscript
	{mso-style-name:Superscript;
	font-family:"Albertus",sans-serif;
	font-weight:bold;
	vertical-align:super;}
p.sponUdate, li.sponUdate, div.sponUdate
	{mso-style-name:sponUdate;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.BoldItal
	{mso-style-name:BoldItal;
	font-weight:bold;
	font-style:italic;}
p.amendfooter, li.amendfooter, div.amendfooter
	{mso-style-name:amendfooter;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.HangingSup, li.HangingSup, div.HangingSup
	{mso-style-name:HangingSup;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.HangingTableBottom, li.HangingTableBottom, div.HangingTableBottom
	{mso-style-name:HangingTableBottom;
	margin-top:0in;
	margin-right:1.0in;
	margin-bottom:0in;
	margin-left:.8in;
	margin-bottom:.0001pt;
	text-indent:-.8in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.HangingTableTop, li.HangingTableTop, div.HangingTableTop
	{mso-style-name:HangingTableTop;
	margin-top:0in;
	margin-right:.5in;
	margin-bottom:0in;
	margin-left:.8in;
	margin-bottom:.0001pt;
	text-indent:-.8in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:"Segoe UI",sans-serif;
	letter-spacing:.2pt;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:8.5in 14.0in;
	margin:1.5in 1.0in 1.0in 1.0in;}
div.WordSection1
	{page:WordSection1;}
@page WordSection2
	{size:8.5in 14.0in;
	margin:1.5in 113.75pt 1.0in 113.75pt;}
div.WordSection2
	{page:WordSection2;}
@page WordSection3
	{size:8.5in 14.0in;
	margin:1.0in 1.75in 1.2in 2.0in;}
div.WordSection3
	{page:WordSection3;}
-->
</style>

</head>

<body lang=EN-US>

<div class=WordSection1>

<p class=bpuBill><a name=bpuFrontPg></a>ASSEMBLY, No. 797 </p>

<p class=bpuWpGraphic></p>

<p class=bpuState>STATE OF NEW JERSEY</p>

<p class=bpuLegislature>221st LEGISLATURE</p>

<p class=bpuWpGraphic>  </p>

<p class=bpuIntro>PRE-FILED FOR INTRODUCTION IN THE 2024 SESSION</p>

<p class=bpuIntro>&nbsp;</p>

</div>

<span style='font-size:12.0pt;line-height:120%;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:auto'>
</span>

<div class=WordSection2>

<p class=bpuIntro>&nbsp;</p>

<p class=bpuSponsor>Sponsored by:</p>

<p class=bpuSponsor>Assemblyman  GREGORY P. MCGUCKIN</p>

<p class=bpuSponsor>District 10 (Monmouth and Ocean)</p>

<p class=bpuSponsor>Assemblyman  PAUL KANITRA</p>

<p class=bpuSponsor>District 10 (Monmouth and Ocean)</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>SYNOPSIS</p>

<p class=bpuNormText>     Limits upfront costs for oral anticancer medications
for persons covered under certain health benefits plans. </p>

<p class=bpuNormText>&nbsp;</p>

<p class=bpuSponsor>CURRENT VERSION OF TEXT </p>

<p class=bpuNormText>     Introduced Pending Technical Review by Legislative
Counsel.</p>

<p class=bpuNormText>   </p>

</div>

<span style='font-size:10.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div class=WordSection3>

<p class=HangingAnAct style='line-height:150%'><span class=BillHead>An Act</span><span
class=HangingAnActChar> </span>concerning health benefits coverage for oral
anticancer medications and amending various parts of the statutory law.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     <span class=BillHeading2>Be It
Enacted </span><span class=BillLanguage>by the Senate and General Assembly of
the State of New Jersey:</span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     1.    Section 1 of P.L.2011,
c.188 (C.17:48-6jj) is amended to read as follows:</p>

<p class=MsoNormal style='line-height:150%'>     1.    a.  A hospital service
corporation contract that provides hospital and medical expense benefits and is
delivered, issued, executed, or renewed in this State pursuant to P.L.1938,
c.366 (C.17:48-1 et seq.), or approved for issuance or renewal in this State by
the Commissioner of Banking and Insurance, on or after the effective date of
this act, shall provide coverage for expenses for prescribed, orally
administered anticancer medications used to kill or slow the growth of
cancerous cells on a basis no less favorable than the contract provides for
intravenously administered or injected anticancer medications.</p>

<p class=MsoNormal style='line-height:150%'>     b.    Pursuant to subsection
a. of this section, coverage for expenses for prescribed, orally administered
anticancer medications used to kill or slow the growth of cancerous cells shall
not be subject to any prior authorization, dollar limit, copayment, deductible
or coinsurance provision that does not apply to intravenously administered or
injected anticancer medications.</p>

<p class=MsoNormal style='line-height:150%'>     c.     A hospital service
corporation contract shall not achieve compliance with the provisions of this
section by imposing an increase in patient cost sharing, including any
copayment, deductible or coinsurance, for anticancer medications, whether
intravenously administered or injected or orally administered, that are covered
under the contract as of the effective date of this act.</p>

<p class=MsoNormal style='line-height:150%'>     d.    <u>Except for any
copayment, deductible or coinsurance required to be paid by the covered person
pursuant to the contract, a contract shall not require a covered person to pay
any additional upfront cost or out of pocket expense for orally administered
anticancer medications, even if reimbursement for that cost or expense is to be
provided to the covered person at a later date.</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>e.</u>     This section
shall apply to those hospital service corporation contracts in which the
hospital service corporation has reserved the right to change the premium.</p>

<p class=MsoNormal style='line-height:150%'>(cf: P.L.2011, c.188, s.1)</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     2.    Section 2 of P.L.2011,
c.188 (C.17:48A-7gg) is amended to read as follows:</p>

<p class=MsoNormal style='line-height:150%'>     2.    a.  A medical service
corporation contract that provides hospital and medical expense benefits and is
delivered, issued, executed, or renewed in this State pursuant to P.L.1940, c.74
(C.17:48A-1 et seq.), or approved for issuance or renewal in this State by the
Commissioner of Banking and Insurance, on or after the effective date of this
act, shall provide coverage for expenses for prescribed, orally administered
anticancer medications used to kill or slow the growth of cancerous cells on a
basis no less favorable than the contract provides for intravenously
administered or injected anticancer medications.</p>

<p class=MsoNormal style='line-height:150%'>     b.    Pursuant to subsection
a. of this section, coverage for expenses for prescribed, orally administered
anticancer medications used to kill or slow the growth of cancerous cells shall
not be subject to any prior authorization, dollar limit, copayment, deductible
or coinsurance provision that does not apply to intravenously administered or
injected anticancer medications.</p>

<p class=MsoNormal style='line-height:150%'>     c.     A medical service
corporation contract shall not achieve compliance with the provisions of this
section by imposing an increase in patient cost sharing, including any
copayment, deductible or coinsurance, for anticancer medications, whether
intravenously administered or injected or orally administered, that are covered
under the contract as of the effective date of this act.</p>

<p class=MsoNormal style='line-height:150%'>     d.    <u>Except for any
copayment, deductible or coinsurance required to be paid by the covered person
pursuant to the contract, a contract shall not require a covered person to pay
any additional upfront cost or out of pocket expense for orally administered
anticancer medications, even if reimbursement for that cost or expense is to be
provided to the covered person at a later date.</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>e.</u>     This section
shall apply to those medical service corporation contracts in which the medical
service corporation has reserved the right to change the premium.</p>

<p class=MsoNormal style='line-height:150%'>(cf: P.L.2011, c.188, s.2)</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     3.    Section 3 of P.L.2011, c.188
(C.17:48E-35.34) is amended to read as follows:</p>

<p class=MsoNormal style='line-height:150%'>     3.    a.  A health service
corporation contract that provides hospital and medical expense benefits and is
delivered, issued, executed, or renewed in this State pursuant to P.L.1985,
c.236 (C.17:48E-1 et seq.), or approved for issuance or renewal in this State
by the Commissioner of Banking and Insurance, on or after the effective date of
this act, shall provide coverage for expenses for prescribed, orally
administered anticancer medications used to kill or slow the growth of
cancerous cells on a basis no less favorable than the contract provides for
intravenously administered or injected anticancer medications.</p>

<p class=MsoNormal style='line-height:150%'>     b.    Pursuant to subsection
a. of this section, coverage for expenses for prescribed, orally administered
anticancer medications used to kill or slow the growth of cancerous cells shall
not be subject to any prior authorization, dollar limit, copayment, deductible
or coinsurance provision that does not apply to intravenously administered or
injected anticancer medications.</p>

<p class=MsoNormal style='line-height:150%'>     c.     A health service
corporation contract shall not achieve compliance with the provisions of this
section by imposing an increase in patient cost sharing, including any
copayment, deductible or coinsurance, for anticancer medications, whether
intravenously administered or injected or orally administered, that are covered
under the contract as of the effective date of this act.</p>

<p class=MsoNormal style='line-height:150%'>     d.    <u>Except for any
copayment, deductible or coinsurance required to be paid by the covered person
pursuant to the contract, a contract shall not require a covered person to pay
any additional upfront cost or out of pocket expense for orally administered
anticancer medications, even if reimbursement for that cost or expense is to be
provided to the covered person at a later date.</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>e.</u>     This section
shall apply to those health service corporation contracts in which the health
service corporation has reserved the right to change the premium.</p>

<p class=MsoNormal style='line-height:150%'>(cf: P.L.2011, c.188, s.3)</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     4.    Section 4 of P.L.2011,
c.188 (C.17B:26-2.1dd) is amended to read as follows:</p>

<p class=MsoNormal style='line-height:150%'>     4.    a.  An individual health
insurance policy that provides hospital and medical expense benefits and is
delivered, issued, executed, or renewed in this State pursuant to
N.J.S.17B:26-1 et seq., or approved for issuance or renewal in this State by
the Commissioner of Banking and Insurance, on or after the effective date of
this act, shall provide coverage for expenses for prescribed, orally
administered anticancer medications used to kill or slow the growth of
cancerous cells on a basis no less favorable than the policy provides for
intravenously administered or injected anticancer medications.</p>

<p class=MsoNormal style='line-height:150%'>     b.    Pursuant to subsection
a. of this section, coverage for expenses for prescribed, orally administered
anticancer medications used to kill or slow the growth of cancerous cells shall
not be subject to any prior authorization, dollar limit, copayment, deductible
or coinsurance provision that does not apply to intravenously administered or
injected anticancer medications.</p>

<p class=MsoNormal style='line-height:150%'>     c.     An individual health
insurance policy shall not achieve compliance with the provisions of this
section by imposing an increase in patient cost sharing, including any
copayment, deductible or coinsurance, for anticancer medications, whether
intravenously administered or injected or orally administered, that are covered
under the policy as of the effective date of this act.</p>

<p class=MsoNormal style='line-height:150%'>     d.    <u>Except for any
copayment, deductible or coinsurance required to be paid by the covered person
pursuant to the policy, a policy shall not require an insured to pay any additional
upfront cost or out of pocket expense for orally administered anticancer
medications, even if reimbursement for that cost or expense is to be provided to
the covered person at a later date.</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>e.</u>     This section
shall apply to those policies in which the insurer has reserved the right to
change the premium.</p>

<p class=MsoNormal style='line-height:150%'>(cf: P.L.2011, c.188, s.4)</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     5.    Section 5 of P.L.2011,
c.188 (C.17B:27-46.1jj) is amended to read as follows:</p>

<p class=MsoNormal style='line-height:150%'>     5.    a.  A group health
insurance policy that provides hospital and medical expense benefits and is
delivered, issued, executed, or renewed in this State pursuant to
N.J.S.17B:27-26 et seq., or approved for issuance or renewal in this State by
the Commissioner of Banking and Insurance, on or after the effective date of this
act, shall provide coverage for expenses for prescribed, orally administered
anticancer medications used to kill or slow the growth of cancerous cells on a
basis no less favorable than the policy provides for intravenously administered
or injected anticancer medications. </p>

<p class=MsoNormal style='line-height:150%'>     b.    Pursuant to subsection
a. of this section, coverage for expenses for prescribed, orally administered
anticancer medications used to kill or slow the growth of cancerous cells shall
not be subject to any prior authorization, dollar limit, copayment, deductible
or coinsurance provision that does not apply to intravenously administered or
injected anticancer medications.</p>

<p class=MsoNormal style='line-height:150%'>     c.     A group health
insurance policy shall not achieve compliance with the provisions of this
section by imposing an increase in patient cost sharing, including any
copayment, deductible or coinsurance, for anticancer medications, whether
intravenously administered or injected or orally administered, that are covered
under the policy as of the effective date of this act.</p>

<p class=MsoNormal style='line-height:150%'>     d.    <u>Except for any
copayment, deductible or coinsurance required to be paid by the covered person
pursuant to the policy, a policy shall not require a covered person to pay any additional
upfront cost or out of pocket expense for orally administered anticancer
medications, even if reimbursement for that cost or expense is to be provided to
the covered person at a later date.</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>e.</u>     This section
shall apply to those policies in which the insurer has reserved the right to
change the premium.</p>

<p class=MsoNormal style='line-height:150%'>(cf: P.L.2011, c.188, s.5)</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     6.    Section 6 of P.L.2011,
c.188 (C.17B:27A-7.17) is amended to read as follows:</p>

<p class=MsoNormal style='line-height:150%'>     6.    a.  An individual health
benefits plan that is delivered, issued, executed, or renewed in this State
pursuant to P.L.1992, c.161 (C.17B:27A-2 et seq.), on or after the effective
date of this act, shall provide coverage for expenses for prescribed, orally
administered anticancer medications used to kill or slow the growth of
cancerous cells on a basis no less favorable than the plan provides for
intravenously administered or injected anticancer medications. </p>

<p class=MsoNormal style='line-height:150%'>     b.    Pursuant to subsection
a. of this section, coverage for expenses for prescribed, orally administered
anticancer medications used to kill or slow the growth of cancerous cells shall
not be subject to any prior authorization, dollar limit, copayment, deductible
or coinsurance provision that does not apply to intravenously administered or
injected anticancer medications.</p>

<p class=MsoNormal style='line-height:150%'>     c.     An individual health
benefits plan shall not achieve compliance with the provisions of this section
by imposing an increase in patient cost sharing, including any copayment,
deductible or coinsurance, for anticancer medications, whether intravenously
administered or injected or orally administered, that are covered under the
plan as of the effective date of this act.</p>

<p class=MsoNormal style='line-height:150%'>     d.    <u>Except for any
copayment, deductible or coinsurance required to be paid by the covered person
pursuant to the health benefits plan, a health benefits plan shall not require
a covered person to pay any additional upfront cost or out of pocket expense
for orally administered anticancer medications, even if reimbursement for that
cost or expense is to be provided to the covered person at a later date.</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>e.</u>     This section
shall apply to those health benefits plans in which the carrier has reserved
the right to change the premium.</p>

<p class=MsoNormal style='line-height:150%'>(cf: P.L.2011, c.188, s.6)</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     7.    Section 7 of P.L.2011,
c.188 (C.17B:27A-19.21) is amended to read as follows:</p>

<p class=MsoNormal style='line-height:150%'>     7.    a.   A small employer
health benefits plan that is delivered, issued, executed, or renewed in this
State pursuant to P.L.1992, c.162 (C.17B:27A-17 et seq.), on or after the
effective date of this act, shall provide coverage for expenses for prescribed,
orally administered anticancer medications used to kill or slow the growth of
cancerous cells on a basis no less favorable than the plan provides for
intravenously administered or injected anticancer medications. </p>

<p class=MsoNormal style='line-height:150%'>     b.    Pursuant to subsection
a. of this section, coverage for expenses for prescribed, orally administered
anticancer medications used to kill or slow the growth of cancerous cells shall
not be subject to any prior authorization, dollar limit, copayment, deductible
or coinsurance provision that does not apply to intravenously administered or
injected anticancer medications.</p>

<p class=MsoNormal style='line-height:150%'>     c.     A small employer health
benefits plan shall not achieve compliance with the provisions of this section
by imposing an increase in patient cost sharing, including any copayment,
deductible or coinsurance, for anticancer medications, whether intravenously
administered or injected or orally administered, that are covered under the
plan as of the effective date of this act.</p>

<p class=MsoNormal style='line-height:150%'>     d.    <u>Except for any
copayment, deductible or coinsurance required to be paid by the covered person
pursuant to the health benefits plan, a health benefits plan shall not require
a covered person to pay any additional upfront cost or out of pocket expense
for orally administered anticancer medications, even if reimbursement for that
cost or expense is to be provided to the covered person at a later date.</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>e.</u>     This section
shall apply to those health benefits plans in which the carrier has reserved
the right to change the premium.</p>

<p class=MsoNormal style='line-height:150%'>(cf: P.L.2011, c.188, s.7)</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     8.    Section 8 of P.L.2011,
c.188 (C.26:2J-4.35) is amended to read as follows:</p>

<p class=MsoNormal style='line-height:150%'>     8.    a.   A health maintenance
organization contract for health care services that is delivered, issued,
executed, or renewed in this State pursuant to P.L.1973, c.337 (C.26:2J-1 et
seq.), or approved for issuance or renewal in this State by the Commissioner of
Banking and Insurance, on or after the effective date of this act, shall
provide health care services for prescribed, orally administered anticancer
medications used to kill or slow the growth of cancerous cells on a basis no
less favorable than the contract provides for covered intravenously
administered or injected anticancer medications.</p>

<p class=MsoNormal style='line-height:150%'>     b.    Pursuant to subsection
a. of this section, coverage for expenses for prescribed, orally administered
anticancer medications used to kill or slow the growth of cancerous cells shall
not be subject to any prior authorization, dollar limit, copayment, deductible
or coinsurance provision that does not apply to intravenously administered or
injected anticancer medications.</p>

<p class=MsoNormal style='line-height:150%'>     c.     A health maintenance
organization contract shall not achieve compliance with the provisions of this
section by imposing an increase in patient cost sharing, including any
copayment, deductible or coinsurance, for anticancer medications, whether
intravenously administered or injected or orally administered, that are covered
under the contract as of the effective date of this act.</p>

<p class=MsoNormal style='line-height:150%'>     d.    <u>Except for any
copayment, deductible or coinsurance required to be paid by the covered person
pursuant to the contract, a contract shall not require a covered person to pay
any additional upfront cost or out of pocket expense for orally administered
anticancer medications, even if reimbursement for that cost or expense is to be
provided to the covered person at a later date.</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>e.</u>     This section
shall apply to those contracts for health care services under which the right
to change the schedule of charges for enrollee coverage is reserved.</p>

<p class=MsoNormal style='line-height:150%'>(cf: P.L.2011, c.188, s.8)</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     9.    Section 9 of P.L.2011,
c.188 (C.52:14-17.29r) is amended to read as follows:</p>

<p class=MsoNormal style='line-height:150%'>     9.    a.   The State Health
Benefits Commission shall ensure that every contract purchased on or after the
effective date of this act that provides hospital or medical expense benefits
shall provide coverage for expenses for prescribed, orally administered
anticancer medications used to kill or slow the growth of cancerous cells on a
basis no less favorable than the contract provides for intravenously
administered or injected anticancer medications.  </p>

<p class=MsoNormal style='line-height:150%'>     b.    Pursuant to subsection
a. of this section, coverage for expenses for prescribed, orally administered
anticancer medications used to kill or slow the growth of cancerous cells shall
not be subject to any prior authorization, dollar limit, copayment, deductible
or coinsurance provision that does not apply to intravenously administered or
injected anticancer medications.</p>

<p class=MsoNormal style='line-height:150%'>     c.     A State Health Benefits
Commission contract shall not achieve compliance with the provisions of this
section by imposing an increase in patient cost sharing, including any
copayment, deductible or coinsurance, for anticancer medications, whether intravenously
administered or injected or orally administered, that are covered under the
contract as of the effective date of this act.</p>

<p class=MsoNormal style='line-height:150%'>     <u>d.    Except for any
copayment, deductible or coinsurance required to be paid by the covered person
pursuant to the contract, a contract shall not require a covered person to pay
any additional upfront cost or out of pocket expense for orally administered
anticancer medications, even if reimbursement for that cost or expense is to be
provided to the covered person at a later date.</u></p>

<p class=MsoNormal style='line-height:150%'>(cf: P.L.2011, c.188, s.9)</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     10.  Section 10 of P.L.2011,
c.188 (C.52:14-17.46.6c) is amended to read as follows:</p>

<p class=MsoNormal style='line-height:150%'>     10.     a.   The School
Employees' Health Benefits Commission shall ensure that every contract
purchased on or after the effective date of this act that provides hospital or
medical expense benefits shall provide coverage for expenses for prescribed,
orally administered anticancer medications used to kill or slow the growth of
cancerous cells on a basis no less favorable than the contract provides for
intravenously administered or injected anticancer medications. </p>

<p class=MsoNormal style='line-height:150%'>     b.    Pursuant to subsection
a. of this section, coverage for expenses for prescribed, orally administered
anticancer medications used to kill or slow the growth of cancerous cells shall
not be subject to any prior authorization, dollar limit, copayment, deductible
or coinsurance provision that does not apply to intravenously administered or
injected anticancer medications.</p>

<p class=MsoNormal style='line-height:150%'>     c.     A School Employees'
Health Benefits Commission contract shall not achieve compliance with the
provisions of this section by imposing an increase in patient cost sharing,
including any copayment, deductible or coinsurance, for anticancer medications,
whether intravenously administered or injected or orally administered, that are
covered under the contract as of the effective date of this act.</p>

<p class=MsoNormal style='line-height:150%'>     <u>d.    Except for any
copayment, deductible or coinsurance required to be paid by the covered person
pursuant to the contract, a contract shall not require a covered person to pay
any additional upfront cost or out of pocket expense for orally administered
anticancer medications, even if reimbursement for that cost or expense is to be
provided to the covered person at a later date.</u></p>

<p class=MsoNormal style='line-height:150%'>(cf: P.L.2011, c.188, s.10)</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     11.  This act shall take
effect immediately and shall apply to all contracts and policies issued on or
after the effective date.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:150%'>STATEMENT</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     This bill limits the amount
that a covered person is required to pay upfront in order to obtain oral
anticancer medications by amending P.L.2011, c. 188, which requires health
insurers, the State Health Benefits Program, and the School Employees Health
Benefits Program to cover oral anticancer medications on a basis no less
favorable than intravenous anticancer medications.</p>

<p class=MsoNormal style='line-height:150%'>     Specifically, the bill
provides that, except for any copayment, deductible or coinsurance required to
be paid by the covered person pursuant to the contract or policy, a contract or
policy shall not require a covered person to pay any additional upfront cost or
out of pocket expense for orally administered anticancer medications, even if
reimbursement for that cost or expense is to be provided to the covered person
at a later date.</p>

<p class=MsoNormal style='line-height:150%'>     Due to the extremely high cost
of many oral anticancer medications, many patients cannot afford to pay for
these medications upfront and wait for reimbursement from their insurer or
health benefits plan at a later date.  This bill attempts to remedy these
situations by limiting upfront costs to the patients copayment, deductible or
coinsurance.</p>

</div>

</body>

</html>
